| 6.2 2.97 (91.95%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.5 |
1-year : | 11.68 |
| Resists | First : | 7.28 |
Second : | 10 |
| Pivot price | 3.44 |
|||
| Supports | First : | 2.89  |
Second : | 2.4 |
| MAs | MA(5) : | 3.83 |
MA(20) : | 3.39 |
| MA(100) : | 3.51 |
MA(250) : | 4.01 |
|
| MACD | MACD : | 0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 49.7 |
D(3) : | 52.6 |
| RSI | RSI(14): 87.3 |
|||
| 52-week | High : | 10 | Low : | 2.55 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GNTA ] has closed above the upper band by 43.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 254.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.01 - 10.05 | 10.05 - 10.1 |
| Low: | 5.61 - 5.64 | 5.64 - 5.67 |
| Close: | 6.15 - 6.2 | 6.2 - 6.25 |
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Fri, 24 Oct 2025
Nasdaq Surges 1%; Procter & Gamble Posts Upbeat Earnings - Benzinga
Fri, 24 Oct 2025
GNTA’s Unexpected Surge: What’s Driving Prices? - StocksToTrade
Fri, 24 Oct 2025
GNTA Stock Price Soars: What Next for Investors? - timothysykes.com
Fri, 24 Oct 2025
Why Is Genenta Science Stock Skyrocketing Friday? - Genenta Science (NASDAQ:GNTA) - Benzinga
Fri, 24 Oct 2025
Genenta Science, Anemocyte enter pact to advance Plasmid DNA technology - TipRanks
Fri, 24 Oct 2025
Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production - MarketScreener
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 18 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 39.1 (%) |
| Held by Institutions | 10.7 (%) |
| Shares Short | 1 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | -0.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.62 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.6 % |
| Return on Equity (ttm) | -60.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -11.28 |
| PEG Ratio | 0 |
| Price to Book value | 9.84 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|